期刊
CURRENT ONCOLOGY REPORTS
卷 23, 期 2, 页码 -出版社
SPRINGER
DOI: 10.1007/s11912-020-01003-9
关键词
Neuroendocrine prostate cancer; Lineage plasticity; AR indifference; Epigenetics; Castration resistance
类别
资金
- Uehara Memorial Foundation Fellowship
- Prostate Cancer Foundation
- National Cancer Institute [R37 CA241486-01A1]
- Department of Defense PCRP [W81XWH-17-1-0653]
NEPC can develop de novo but more commonly arises as a result of lineage plasticity, where prostate cancer cells adopt alternative lineage programs to bypass therapy. Genomic analyses from patient biopsies combined with preclinical modeling have further driven tumor proliferation and expression of downstream neuronal and neuroendocrine lineage pathways.
Purpose of Review Neuroendocrine prostate cancer (NEPC) is an aggressive histologic subtype of prostate cancer that most commonly arises in later stages of prostate cancer as a mechanism of treatment resistance. The poor prognosis of NEPC is attributed in part to late diagnosis and a lack of effective therapeutic agents. Here, we review the clinical and molecular features of NEPC based on recent studies and outline future strategies and directions. Recent Findings NEPC can arise de novo but most commonly develops as a result of lineage plasticity whereby prostate cancer cells adopt alternative lineage programs as a means to bypass therapy. Dependence on androgen receptor (AR) signaling is lost as tumors progress from a prostate adenocarcinoma to a NEPC histology, typically manifested by the downregulation of AR, PSA, and PSMA expression in tumors. Genomic analyses from patient biopsies combined with preclinical modeling have pointed to loss of tumor suppressors RB1 and TP53 as key facilitators of lineage plasticity. Activation of oncogenic drivers combined with significant epigenetic changes (e.g., EZH2 overexpression, DNA methylation) further drives tumor proliferation and expression of downstream neuronal and neuroendocrine lineage pathways controlled in part by pioneer and lineage determinant transcription factors (e.g., SOX2, ASCL1, BRN2). These biologic insights have provided a framework for the study of this subgroup of advanced prostate cancers and have started to provide rationale for the development of biomarker-driven therapeutic strategies. Summary Further study of the dynamic process that leads to NEPC is required for the development of effective strategies to identify and treat patients developing lineage plasticity as a mechanism of treatment resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据